 - Prior therapy with antibody or drug specifically targeting T cell regulatory proteins, including but not limited to: Prior immunotherapy with IL-2 or IFN-α, or an anti-PD-1 including nivolumab, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 CTLA-4 antibody including ipilimumab, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways. 